Blincyto Approved as Consolidation for CD19-Positive Philadelphia Chromosome–Negative B-Cell Precursor ALL

The FDA has approved blinatumomab (Blincyto, Amgen) for adult and pediatric patients aged 1 month and older with CD19-positive Philadelphia chromosome–negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL) in the consolidation phase of multiphase chemotherapy.

Efficacy was evaluated in Study E1910 (ClinicalTrials.gov. Identifier: NCT02003222), a randomized controlled trial in adult patients with newly diagnosed Ph-negative BCP ALL. Eligible patients in hematologic